@Article{or.2022.023346,
AUTHOR = {NIMA HEMMAT, MOHAMMAD AMIN DOUSTVANDI, ZAHRA ASADZADEH, AHAD MOKHTARZADEH, BEHZAD BARADARAN, HOSSEIN BANNAZADEH BAGHI},
TITLE = {Suppression of human papillomavirus type 16 E5 oncoprotein: A  promising step in fostering the treatment of cervical cancer},
JOURNAL = {Oncology Research},
VOLUME = {29},
YEAR = {2021},
NUMBER = {2},
PAGES = {141--148},
URL = {http://www.techscience.com/or/v29n2/48803},
ISSN = {1555-3906},
ABSTRACT = {Cervical cancer is a growing global disease in developing countries. Persistent infection with human
papillomaviruses (HPV) is an essential causative agent in this type of cancer. Several studies demonstrate HPV E5
oncoprotein can impress the normal life cycle of HPV-infected cells by targeting some pivotal cellular signaling
pathways, such as the epidermal growth factor receptor (EGFR) signaling pathway. In this study, we used E5-siRNA
to knockdown that essential oncogene and considered the effect of E5 silencing on proliferation, apoptosis, cell cycle,
apoptosis-related gene expression, and the initiator of the EGFR signaling pathway in cervical cancer cells. The results
demonstrate that E5 plays an essential role in the proliferation and inhibited apoptosis in cervical cancer.
Furthermore, silencing E5 reduces proliferation, increases apoptosis, and elevates related-genes expression of these
malignant cells. Overall, E5 suppression may be appropriate for ameliorating cervical cancer progression.},
DOI = {10.32604/or.2022.023346}
}